Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588679 · ClinicalTrials.gov registry record · NA
Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 265
- Enrollment target
NCT00588679: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00588679 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 265 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588679, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 265 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the benefits of Magnetic Resonance Imaging (MRI) combined with Magnetic Resonance Spectroscopic Imaging (MRSI), on an instrument called a 3.0 Tesla (T) MR scanner.
Interventions
- OTHER Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2006-08-22 |
| Est. Completion | 2019-03-06 |
| Phase | NA |
What the finished NCT00588679 record still lists
NCT00588679 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging is the first listed.
NCT00588679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00588679 about?
NCT00588679 is a clinical study titled "Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla". The purpose of this study is to determine the benefits of Magnetic Resonance Imaging (MRI) combined with Magnetic Resonance Spectroscopic Imaging (MRSI), on an instrument called a 3.0 Tesla (T) MR scanner.
What is the current status of trial NCT00588679?
This trial is currently completed. It is a NA study. The enrollment target is 265 participants. The study started on 2006-08-22. Estimated completion is 2019-03-06.
What interventions are being tested in trial NCT00588679?
The interventions under investigation include: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging (OTHER).
Who is sponsoring clinical trial NCT00588679?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00588679's enrollment target sits among peer trials
265 395th of 2000 higher than 1,606 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI